Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer
Status:
Terminated
Trial end date:
2020-08-15
Target enrollment:
Participant gender:
Summary
This is an open-label phase I/II study for patients with advanced (locally advanced
inoperable or metastatic) triple-negative breast cancer progressing after first-line therapy
receiving ixazomib on days 1, 8, and 15 in combination with carboplatin on days 1, 8, and 15.
Cycles will be repeated every four weeks.